An updated safety review of the current drugs for managing ADHD in children

References

• American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders : DSM-5.5th ed. (WA) D.C: American Psychiatric Association, Inc; 2013.
   Google Scholar
• Dalsgaard S, Thorsteinsson E, Trabjerg BB, et al. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA psychiatry (Chicago, Ill). JAMA Psychiatry. 2019;77(2):155–164. doi: 10.1001/jamapsychiatry.2019.3523
   Web of Science ®Google Scholar
• Bitsko RH, Claussen AH, Lichstein J, et al. Mental Health surveillance among children - United States, 2013-2019. MMWR. 2022;71(2):1–42. doi: 10.15585/mmwr.su7102a1
   PubMedGoogle Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163(4):716–723. doi: 10.1176/ajp.2006.163.4.716
   PubMed Web of Science ®Google Scholar
• Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews. 2021;128:789–818. doi: 10.1016/j.neubiorev.2021.01.022
   PubMed Web of Science ®Google Scholar
• Yoshimasu K, Barbaresi WJ, Colligan RC, et al. Childhood ADHD is strongly associated with a broad range of psychiatric disorders during adolescence: a population-based birth cohort study. J Child Psychol Psychiatry. 2012;53(10):1036–1043. doi: 10.1111/j.1469-7610.2012.02567.x
   PubMed Web of Science ®Google Scholar
• Joelsson P, Chudal R, Gyllenberg D, et al. Demographic characteristics and psychiatric comorbidity of children and adolescents diagnosed with ADHD in specialized healthcare. Child Psychiatry Human Dev. 2016;47(4):574–582. doi: 10.1007/s10578-015-0591-6
   PubMed Web of Science ®Google Scholar
• Prasad V, West J, Sayal K, et al. Injury among children and young people with and without attention‐deficit hyperactivity disorder in the community: the risk of fractures, thermal injuries, and poisonings. Child Care Health Dev. 2018;44(6):871–878. doi: 10.1111/cch.12591
   PubMed Web of Science ®Google Scholar
• Shilon Y, Pollak Y, Aran A, et al. Accidental injuries are more common in children with attention deficit hyperactivity disorder compared with their non-affected siblings. Child Care Health Dev. 2012;38(3):366–370. doi: 10.1111/j.1365-2214.2011.01278.x
   PubMed Web of Science ®Google Scholar
• Sibley MH, Altszuler AR, Morrow AS, et al. Mapping the academic problem behaviors of adolescents with ADHD. Grantee Submission. 2014;29(4):422–437. doi: 10.1037/spq0000071
   Google Scholar
• Evans SC, Cooley JL, Blossom JB, et al. Examining ODD/ADHD symptom dimensions as predictors of social, emotional, and academic trajectories in middle childhood. J Clin Child Adolesc Psychol. 2020;49(6):912–929. doi: 10.1080/15374416.2019.1644645
   PubMed Web of Science ®Google Scholar
• Kent KM, Pelham WE, Molina BSG, et al. The academic experience of male high school students with ADHD. J Abnorm Child Psychol. 2011;39(3):451–462. doi: 10.1007/s10802-010-9472-4
   PubMed Web of Science ®Google Scholar
• Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr. 2007;28(4):265–273. doi: 10.1097/DBP.0b013e31811ff87d
   PubMed Web of Science ®Google Scholar
• Brod M, Schmitt E, Goodwin M, et al. ADHD burden of illness in older adults: a life course perspective. Qual Life Res. 2012;21(5):795–799. doi: 10.1007/s11136-011-9981-9
   PubMed Web of Science ®Google Scholar
• Gordon CT, Fabiano GA. The transition of youth with ADHD into the workforce: review and future directions. Clin Child Fam Psychol Rev. 2019;22(3):316–347. doi: 10.1007/s10567-019-00274-4
   PubMed Web of Science ®Google Scholar
• Aduen PA, Kofler MJ, Cox DJ, et al. Motor vehicle driving in high incidence psychiatric disability: comparison of drivers with ADHD, depression, and no known psychopathology. J Psychiatr Res. 2015;64:59–66. doi: 10.1016/j.jpsychires.2015.03.009
   PubMed Web of Science ®Google Scholar
• Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Allocation. 2005;3(1):5–5. doi: 10.1186/1478-7547-3-5
   PubMedGoogle Scholar
• Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020;395(10222):450–462. British edition. doi: 10.1016/S0140-6736(19)33004-1.
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Krone B, Dittmann RW. Nonstimulant treatments for ADHD. Child and adolescent psychiatric clinics of North America. Child Adolesc Psychiatr Clin N Am. 2022;31(3):417–435. doi: 10.1016/j.chc.2022.03.005
   PubMed Web of Science ®Google Scholar
• Coghill D, Banaschewski T, Cortese S, et al. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD guidelines group (EAGG). Eur Child Adolesc Psychiatry. 2023;32:1337–1361.
   PubMed Web of Science ®Google Scholar
• Catala-Lopez F, Hutton B, Nunez-Beltran A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7):e0180355–e0180355. doi: 10.1371/journal.pone.0180355
   PubMed Web of Science ®Google Scholar
• Childress A. The safety of extended-release drug formulations for the treatment of ADHD. Expert Opin Drug Saf. 2017;16(5):603–615. doi: 10.1080/14740338.2017.1317344
   PubMed Web of Science ®Google Scholar
• Ching C, Eslick GD, Poulton AS. Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit/Hyperactivity disorder: a meta-analysis. JAMA Pediatr. 2019;173(7):630–639. doi: 10.1001/jamapediatrics.2019.0905
   PubMed Web of Science ®Google Scholar
• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi: 10.1016/S2215-0366(18)30269-4
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Evidence reviews for pharmacological efficacy and sequencing pharmacological treatment: attention deficit hyperactivity disorder: diagnosis and management: evidence review. London: National Institute for Health and Care Excellence (NICE); 2018.
   Google Scholar
• Li Y, Gao J, He S, et al. An evaluation on the efficacy and safety of treatments for attention deficit hyperactivity disorder in children and adolescents: a comparison of multiple treatments. Mol Neurobiol. 2017;54(9):6655–6669. doi: 10.1007/s12035-016-0179-6
   PubMed Web of Science ®Google Scholar
• Drugs for ADHD. The medical letter on drugs and therapeutics. CanMed Assoc J. 2015;57(1464):37–40. (English ed).
   Google Scholar
• Cantilena L, Kahn R, Duncan CC, et al. Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants. J Addict Med. 2012;6(4):265–273. doi: 10.1097/ADM.0b013e31826b767f
   PubMed Web of Science ®Google Scholar
• Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26(8):875–897. doi: 10.1007/s00787-017-0962-6
   PubMed Web of Science ®Google Scholar
• Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti‐attention‐deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta‐review of 78 adverse effects. World Psychiatry. 2020;19(2):214–232. doi: 10.1002/wps.20765
   PubMed Web of Science ®Google Scholar
• Correll CU, Cortese S, Croatto G, et al. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. 2021;20(2):244–275. doi: 10.1002/wps.20881
   PubMed Web of Science ®Google Scholar
• Clavenna A, Bonati M. Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Arch Dischildhood. 2014;99(9):866–872. doi: 10.1136/archdischild-2013-304170
   PubMed Web of Science ®Google Scholar
• Groenman AP, Schweren LJS, Dietrich A, et al. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Saf. 2017;16(4):455–464. doi: 10.1080/14740338.2017.1301928
   PubMed Web of Science ®Google Scholar
• Huss M, Duhan P, Gandhi P, et al. Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. Neuropsychiatr Dis Treat. 2017;13:1741–1751. doi: 10.2147/NDT.S130444
   PubMed Web of Science ®Google Scholar
• Cerrillo-Urbina AJ, García-Hermoso A, Pardo-Guijarro MJ, et al. The effects of long-acting stimulant and nonstimulant medications in children and adolescents with attention-deficit/Hyperactivity disorder: a meta-analysis of randomized controlled trials. J Child Adolesc Psychopharmacol. 2018;28(8):494–507. doi: 10.1089/cap.2017.0151
   PubMed Web of Science ®Google Scholar
• Faltinsen E, Zwi M, Castells X, et al. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look. BMJ EBM. 2019;24(3):99–102. doi: 10.1136/bmjebm-2018-111110
   Google Scholar
• Drugs for ADHD. Med Lett Drugs Ther. 2020;62(1590):9–15.
   PubMed Web of Science ®Google Scholar
• Storebø O, Ramstad E, Krogh H, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;2016(11). doi: 10.1002/14651858.CD009885.pub2
   Google Scholar
• Padilha SCOS, Virtuoso S, Tonin FS, et al. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. Eur Child Adolesc Psychiatry. 2018;27(10):1335–1345. doi: 10.1007/s00787-018-1125-0
   PubMed Web of Science ®Google Scholar
• Haddad HW, Hankey PB, Ko J, et al. Viloxazine, a non-stimulant norepinephrine reuptake inhibitor, for the treatment of attention deficit hyperactivity disorder: a 3 year update. Health Psychol Res. 2022;10(2):37018–37018. doi: 10.52965/001c.37018
   PubMed Web of Science ®Google Scholar
• Viloxazine ER (Qelbree) for ADHD. Med Lett Drugs Ther. 2021;63(1627):98–100.
   PubMed Web of Science ®Google Scholar
• Masi G, Pfanner C, Liboni F, et al. Acute tolerability of methylphenidate in treatment-naïve children with ADHD: an analysis of naturalistically collected data from clinical practice. Paediatr Drugs. 2022;24(2):147–154. doi: 10.1007/s40272-022-00492-4
   PubMed Web of Science ®Google Scholar
• Storebø O, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies. Cochrane Database Syst Rev. 2018. doi: 10.1002/14651858.CD012069.pub2
   PubMed Web of Science ®Google Scholar
• Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;2016(2):CD009996–CD009996. doi: 10.1002/14651858.CD009996.pub2
   Google Scholar
• Banaschewski T, Gerlach M, Becker K, et al. Trust, but verify. The errors and misinterpretations in the cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie. 2016;44(4):307–314. doi: 10.1024/1422-4917/a000433
   PubMed Web of Science ®Google Scholar
• Gerlach M, Banaschewski T, Coghill D, et al. What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder? Attention deficit and hyperactivity disorders. Atten Def Hyp Disord. 2017;9(1):1–3. doi: 10.1007/s12402-017-0220-2
   PubMedGoogle Scholar
• Steingard R, Taskiran S, Connor DF, et al. New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol. 2019;29(5):324–339. doi: 10.1089/cap.2019.0043
   PubMed Web of Science ®Google Scholar
• Childress A, Ponce De Leon B, Owens M. QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above. Expert Opin Drug Delivery. 2018;15(12):1263–1270. doi: 10.1080/17425247.2018.1545759
   PubMed Web of Science ®Google Scholar
• Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/Hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(8):690–699. doi: 10.1089/cap.2016.0177
   PubMed Web of Science ®Google Scholar
• Wigal SB, Childress A, Berry SA, et al. Optimization of methylphenidate extended-release chewable tablet dose in children with ADHD: open-label dose optimization in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2018;28(5):314–321. doi: 10.1089/cap.2017.0138
   PubMed Web of Science ®Google Scholar
• QUILLICHEW ERTM (methylphenidate hydrochloride) extended-release chewable tablet), CII prescribing information [cited 2022 Dec 31] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207960s000lbl.pdf.
   Google Scholar
• Childress AC, Kollins SH, Foehl HC, et al. Randomized, double-blind, placebo-controlled, flexible-dose titration study of methylphenidate hydrochloride extended-release capsules (aptensio XR) in preschool children with attention-deficit/Hyperactivity disorder. J Child Adolesc Psychopharmacol. 2020;30(2):58–68. doi: 10.1089/cap.2019.0085
   PubMed Web of Science ®Google Scholar
• Wigal SB, Nordbrock E, Adjei AL, et al. Efficacy of methylphenidate hydrochloride extended-release capsules (aptensio XR™) in children and adolescents with attention-deficit/Hyperactivity disorder: a phase III, randomized, double-blind study. CNS Drugs. 2015;29(4):331–340. doi: 10.1007/s40263-015-0241-3
   PubMed Web of Science ®Google Scholar
• APTENSIO XRTM (methylphenidate hydrochloride extended-release capsules), CII prescribing information [cited 2022 Dec 31] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205831s006lbl.pdf
   Google Scholar
• ADHANSIA XRTM (methylphenidate hydrochloride) extended-release capsules, CII [cited 2022 Dec 31] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212038Orig1s000lbl.pdf.
   Google Scholar
• Childress AC, Brams MN, Cutler AJ, et al. Efficacy and safety of multilayer, extended-release methylphenidate (PRC-063) in children 6–12 years of age with attention-deficit/Hyperactivity disorder: a laboratory classroom study. J Child Adolesc Psychopharmacol. 2020;30(10):580–589. doi: 10.1089/cap.2020.0109
   PubMed Web of Science ®Google Scholar
• Weiss MD, Cutler AJ, Kollins SH, et al. Efficacy and safety of a long-acting multilayer-release methylphenidate formulation (PRC-063) in the treatment of adolescent attention-deficit/Hyperactivity disorder: a randomized, double-blind clinical trial with a 6-month open-label extension. J Child Adolesc Psychopharmacol. 2021;31(9):610–622. doi: 10.1089/cap.2021.0034
   PubMed Web of Science ®Google Scholar
• Jornay PM. Evening-dosed methylphenidate for ADHD. Med Lett Drugs Ther. 2019;61(1578): 126–128. (English ed).
   PubMed Web of Science ®Google Scholar
• JORNAY PM (methylphenidate hydrochloride) extended-release capsules, CII prescribing information [cited 2022 Dec 31] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209311s000lbl.pdf
   Google Scholar
• Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/Hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(6):474–482. doi: 10.1089/cap.2017.0084
   PubMed Web of Science ®Google Scholar
• Childress AC, Cutler AJ, Marraffino A, et al. A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/Hyperactivity disorder: an evaluation of safety and efficacy throughout the Day and across settings. J Child Adolesc Psychopharmacol. 2020;30(1):2–14. doi: 10.1089/cap.2019.0070
   PubMed Web of Science ®Google Scholar
• DaytranaTM (transdermal system), CII prescribing information [cited 2022 Dec 31] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021514s011lbl.pdf
   Google Scholar
• Findling RL, Dinh S. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS). CNS Drugs. 2014;28(3):217–228. doi: 10.1007/s40263-014-0141-y
   PubMed Web of Science ®Google Scholar
• COTEMPLA XR-ODT (methylphenidate extended-release orally disintegrating tablets) CII prescribing information [cited 2022 Dec 31] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf
   Google Scholar
• Childress AC, Kollins SH, Cutler AJ, et al. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/Hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66–74. doi: 10.1089/cap.2016.0002
   PubMed Web of Science ®Google Scholar
• A new amphetamine oral suspension (adzenys ER) for ADHD. Med Lett Drugs Ther. 2018;60(1549):e106–8.
   PubMedGoogle Scholar
• ADZENYS XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII prescribing information [cited 2022 Dec 31] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204326s008lbl.pdf
   Google Scholar
• Riesenberg RA, Marraffino A, Engelking D, et al. 2.45 a phase 4, open-label, multicenter, single-dose study of the pharmacokinetics of a novel amphetamine extended-release oral disintegrating tablet formulation (adzenys XR-ODT™) in preschool-aged children. J Am Acad Child Adolesc Psychiatry. 2018;57(10):S173–4. doi: 10.1016/j.jaac.2018.09.133
   Web of Science ®Google Scholar
• Childress AC, Kando JC, King TR, et al. Early-onset efficacy and safety Pilot study of amphetamine extended-release oral suspension in the treatment of children with attention-deficit/Hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019;29(1):2–8. doi: 10.1089/cap.2018.0078
   PubMed Web of Science ®Google Scholar
• Childress AC, Wigal SB, Brams MN, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/Hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018;28(5):306–313. doi: 10.1089/cap.2017.0095
   PubMed Web of Science ®Google Scholar
• Childress AC, Pardo A, King TR, et al. 32 early-onset efficacy and safety Pilot study of amphetamine extended-release oral suspension (AMPH EROS) in the treatment of children with attention-deficit/Hyperactivity disorder. CNS Spectr. 2019;24(1):191–192. doi: 10.1017/S1092852919000269
   Google Scholar
• XR DYNAVELtm (amphetamine) extended-release oral suspension CII prescribing information, DYANAVEL XRTM (amphetamine) extended-release tablets, CII prescribing information [cited 2023 Jan 1] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210526s000lbl.pdf.
   Google Scholar
• Najib J, Didenko E, Meleshkina D, et al. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2020;36(10):1717–1735. doi: 10.1080/03007995.2020.1815002
   PubMed Web of Science ®Google Scholar
• Hansen MV, Darling L, Holst H. Safety and tolerability of Lisdexamfetamine: a retrospective cohort study. CNS Drugs. 2015;29(5):415–423. doi: 10.1007/s40263-015-0246-y
   PubMed Web of Science ®Google Scholar
• Coghill DR, Banaschewski T, Nagy P, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: a phase IV, 2-year, open-label study in Europe. CNS Drugs. 2017;31(7):625–638. doi: 10.1007/s40263-017-0443-y
   PubMed Web of Science ®Google Scholar
• VYVANSETM (lisdexamfetamine dimesylate) capsules, CII prescribing information, VYVANSETM (lisdexamfetamine dimesylate) chewable tablets for oral use, CII prescribing information [cited 2023 Jan 1] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021977s047,208510s004lbl.pdf.
   Google Scholar
• FDA approves amphetamine patch for ADHD. Alcoholism & Drug Abuse Weekly. 2022;34(19):8–8. doi: 10.1002/adaw.33434
   Google Scholar
• XELSTRYMTM (dextroamphetamine) transdermal system, CII prescribing information [cited 2023 Jan 1] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215401s000lbl.pdf
   Google Scholar
• Brams M, Childress AC, Greenbaum M, et al. SHP465 mixed amphetamine salts in the treatment of attention-deficit/Hyperactivity disorder in children and adolescents: results of a randomized, double-blind placebo-controlled study. J Child Adolesc Psychopharmacol. 2018;28(1):19–28. doi: 10.1089/cap.2017.0053
   PubMed Web of Science ®Google Scholar
• MYDAYISTM (mixed salts of a single-entity amphetamine product) extended-release capsules, CII prescribing information [cited 2023 Jan 21] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022063s000lbl.pdf.
   Google Scholar
• Elbe D, Reddy D. Focus on guanfacine extended-release: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2014;23(1):48–60.
   PubMedGoogle Scholar
• CLONIDINE ER (clonidine extended-release tablets), Prescribing Information [cited 2023 Jan 1] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022500lbl.pdf
   Google Scholar
• Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/Hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(2):171–179. doi: 10.1016/j.jaac.2010.11.005
   PubMed Web of Science ®Google Scholar
• Croxtall JD. Clonidine extended-release: in attention-deficit hyperactivity disorder. Paediatr Drugs. 2011;13(5):329–336. doi: 10.2165/11208100-000000000-00000
   PubMed Web of Science ®Google Scholar
• Ming X, Mulvey M, Mohanty S, et al. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesce Health Med Therapeutics. 2011;2:105–112. doi: 10.2147/AHMT.S15672
   PubMedGoogle Scholar
• Faraone SVP, McBurnett KP, FRMDP S, et al. Guanfacine extended release: a novel treatment for attention-deficit/Hyperactivity disorder in children and adolescents. Clin Ther. 2013;35(11):1778–1793. doi: 10.1016/j.clinthera.2013.09.005
   PubMed Web of Science ®Google Scholar
• Childress A, Hoo-Cardiel A, Lang P. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents. Expert Opin Pharmacother. 2020;21(4):417–426. doi: 10.1080/14656566.2019.1706480
   PubMed Web of Science ®Google Scholar
• Wilens TE, Robertson B, Sikirica VP, et al. A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/Hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):916–25.e2. doi: 10.1016/j.jaac.2015.08.016
   PubMed Web of Science ®Google Scholar
• ▼Guanfacine for ADHD in children and adolescents. DTB. 2016;54(5):56–60. doi: 10.1136/dtb.2016.5.0402
   Google Scholar
• Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/Hyperactivity and related disorders. J Child Adolesc Psychopharmacol. 2013;23(5):308–319. doi: 10.1089/cap.2013.0028
   PubMed Web of Science ®Google Scholar
• Martinez-Raga J, Knecht C, de Alvaro R. Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatric disease and treatment. Neuropsychiatr Dis Treat. 2015;11:1359–1370. doi: 10.2147/NDT.S65735
   PubMed Web of Science ®Google Scholar
• Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics (Evanston). 2011;127(6):E1406–13. doi: 10.1542/peds.2010-1260
   PubMed Web of Science ®Google Scholar
• McCracken JT, McGough JJ, Loo SK, et al. Combined stimulant and guanfacine Administration in attention-deficit/Hyperactivity disorder: a controlled, comparative study. J Am Acad Child Adolesc Psychiatry. 2016;55(8):657–66.e1. doi: 10.1016/j.jaac.2016.05.015
   PubMed Web of Science ®Google Scholar
• Bello NT. Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents. Patient Preference Adherence. 2015;9:877–885. doi: 10.2147/PPA.S73167
   PubMed Web of Science ®Google Scholar
• Fu D, Wu D-D, Guo H-L, et al. The mechanism, clinical efficacy, safety, and dosage regimen of atomoxetine for ADHD therapy in children: a narrative review. Front Psychiatry. 2022;12:780921–780921. doi: 10.3389/fpsyt.2021.780921
   PubMed Web of Science ®Google Scholar
• STRATTERATM (atomoxetine) capsules for oral use, prescribing information [cited 1 Jan 2023] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021411s050lbl.pdf
   Google Scholar
• Liu Q, Zhang H, Fang Q, et al. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials. J Clin Exp Neuropsychol. 2017;39(9):854–865. doi: 10.1080/13803395.2016.1273320
   PubMed Web of Science ®Google Scholar
• Cortese S, Panei P, Arcieri R, et al. Safety of methylphenidate and atomoxetine in children with attention-deficit/Hyperactivity disorder (ADHD): data from the Italian national ADHD Registry. CNS Drugs. 2015;29(10):865–877. doi: 10.1007/s40263-015-0266-7
   PubMed Web of Science ®Google Scholar
• Reed VA, Buitelaar JK, Anand E, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/Hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs. 2016;30(7):603–628. doi: 10.1007/s40263-016-0349-0
   PubMed Web of Science ®Google Scholar
• Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: a historical overview and Current status. CNS Drugs. 2021;35(6):643–653. doi: 10.1007/s40263-021-00825-w
   PubMed Web of Science ®Google Scholar
• Balasundaram MK, Singh A. Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication. Drugs & Therapy Perspectives: For Rational Drug Selection And Use. 2022;38(2):77–83. doi: 10.1007/s40267-022-00892-z
   Google Scholar
• Yu C, Garcia-Olivares J, Candler S, et al. new insights into the mechanism of action of Viloxazine: serotonin and norepinephrine modulating properties. JEP. 2020;12:285–300. doi: 10.2147/JEP.S256586
   Google Scholar
• Singh A, Balasundaram MK, Singh A. Viloxazine for attention-deficit hyperactivity disorder: a systematic review and meta-analysis of randomized clinical trials. J Cent Nerv Syst Dis. 2022;14:11795735221092522–11795735221092522. doi: 10.1177/11795735221092522
   Web of Science ®Google Scholar
• Nasser A, Hull JT, Chowdhry FA, et al. 113 phase 3, randomized, double-blind, placebo-controlled study (P303) assessing efficacy and safety of extended-release viloxazine in children with ADHD. CNS Spectr. 2020;25(2):273–274. doi: 10.1017/S1092852920000310
   Google Scholar
• Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (Viloxazine extended-release) in the treatment of attention-deficit/Hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021
   PubMed Web of Science ®Google Scholar
• Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64. doi: 10.1016/j.clinthera.2021.01.027
   PubMedGoogle Scholar
• Mather K, Condren M. Extended-release viloxazine for children and adolescents with attention deficit hyperactivity disorder. J Pediatr Pharmacol Ther. 2022;27(5):409–414. doi: 10.5863/1551-6776-27.5.409
   PubMedGoogle Scholar
• Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS): a retrospective study. Drug Saf. 2002;25(14):1021–1033. doi: 10.2165/00002018-200225140-00004
   PubMed Web of Science ®Google Scholar
• Cheng CP, La Grenade L, Diak I-L, et al. Chemical leukoderma associated with methylphenidate transdermal system: data from the US Food and Drug Administration adverse event reporting system. J Paediatr. 2016;180:241–246. doi: 10.1016/j.jpeds.2016.09.008
   PubMed Web of Science ®Google Scholar
• Eiland LS, Bell EA, Erramouspe J. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/Hyperactivity disorder in children. Ann Pharmacother. 2014;48(10):1350–1355. doi: 10.1177/1060028014541791
   PubMed Web of Science ®Google Scholar
• Torres-Acosta N, O’Keefe JH, O’Keefe CL, et al. Cardiovascular effects of ADHD therapies JACC review topic of the Week. J Am Coll Cardiol. 2020;76(7):858–866. doi: 10.1016/j.jacc.2020.05.081
   PubMed Web of Science ®Google Scholar
• Martinez-Raga J, Knecht C, Szerman N, et al. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 2013;27(1):15–30. doi: 10.1007/s40263-012-0019-9
   PubMed Web of Science ®Google Scholar
• Yamaguchi I, Hanevold C. Evaluation and management of elevated blood pressure in children and adolescents with attention deficit hyperactivity disorder. Curr Hypertens Rep. 2019;21(8):60–66. doi: 10.1007/s11906-019-0968-1
   PubMed Web of Science ®Google Scholar
• Cao C, Lorenz ML, Sojka P, et al. Hypertensive crisis in a pediatric patient experiencing clonidine withdrawal. Case Rep Pediatr 2022. Acceccsed Mar 22 2022;2022:1–4. doi: 10.1155/2022/9005063
   Google Scholar
• Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, Evaluation, and treatment of attention-deficit/Hyperactivity disorder in children and adolescents. Pediatrics (Evanston). 2011;128(5):1007–1022.
   PubMed Web of Science ®Google Scholar
• Martinez-Raga J, Ferreros A, Knecht C, et al. Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes. Ther Adv Drug Saf. 2017;8(3):87–99. doi: 10.1177/2042098616679636
   PubMed Web of Science ®Google Scholar
• Jackson JW. The cardiovascular safety of methylphenidate. BMJ. 2016;353:i2874–i2874. doi: 10.1136/bmj.i2874
   PubMedGoogle Scholar
• Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–1904. doi: 10.1056/NEJMoa1110212
   PubMed Web of Science ®Google Scholar
• Olfson M, Huang C, Gerhard T, et al. Stimulants and cardiovascular events in youth with attention-deficit/Hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(2):147–156. doi: 10.1016/j.jaac.2011.11.008
   PubMed Web of Science ®Google Scholar
• Dalsgaard S, Kvist AP, Leckman JF, et al. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol. 2014;24(6):302–310. doi: 10.1089/cap.2014.0020
   PubMed Web of Science ®Google Scholar
• Shin J-Y, Roughead EE, Park B-J, et al. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ. 2016;353:i3123–i3123.
   PubMedGoogle Scholar
• Leeman-Markowski BA, Adams J, Martin SP, et al. Methylphenidate for attention problems in epilepsy patients: safety and efficacy. Epilepsy Behav. 2021;115:107627–107627. doi: 10.1016/j.yebeh.2020.107627
   PubMed Web of Science ®Google Scholar
• Andrade C. Methylphenidate and the risk of new-onset seizures. J Clin Psychiatry. 2020 Jul 21;81(4):20f13586. doi: 10.4088/JCP.20f13586
   PubMed Web of Science ®Google Scholar
• Wiggs KK, Chang Z, Quinn PD, et al. Attention-deficit/hyperactivity disorder medication and seizures. Neurology. 2018;90(13):E1104–10. doi: 10.1212/WNL.0000000000005213
   PubMed Web of Science ®Google Scholar
• Santos K, Palmini A, Radziuk AL, et al. The impact of methylphenidate on seizure frequency and severity in children with attention‐deficit–hyperactivity disorder and difficult‐to‐treat epilepsies. Dev Med Child Neurol. 2013;55(7):654–660. doi: 10.1111/dmcn.12121
   PubMed Web of Science ®Google Scholar
• Ravi M, Epilepsy IA. Attention-deficit/Hyperactivity disorder and methylphenidate: critical examination of guiding evidence. (The JCACAP). 2015;25(1):50–58.
   Google Scholar
• Park J, Choi H-W, Yum M-S, et al. Relationship between aggravation of seizures and methylphenidate treatment in subjects with attention-deficit/Hyperactivity disorder and epilepsy. J Child Adolesc Psychopharmacol. 2018;28(8):537–546. doi: 10.1089/cap.2017.0070
   PubMed Web of Science ®Google Scholar
• Brikell I, Ghirardi L, Chang Z, et al. ADHD medications and the risk of epileptic seizures: a pharmacoepidemiological study using nationwide register data. Eur Neuropsychopharmacol. 2017;27(Suppl. 4):S1113–4. doi: 10.1016/S0924-977X(17)31930-2
   Google Scholar
• Brikell I, Chen Q, Kuja‐Halkola R, et al. Medication treatment for attention‐deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy. Epilepsia (Copenhagen). 2019;60(2):284–293. doi: 10.1111/epi.14640
   PubMed Web of Science ®Google Scholar
• Man KKC, Lau WCY, Coghill D, et al. Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study. The Lancet Child Adol Health. 2020;4(6):435–443. doi: 10.1016/S2352-4642(20)30100-0
   Web of Science ®Google Scholar
• McAfee AT, Landon J, Jones M, et al. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications. Pharmacoepidemiol Drug Saf. 2013;22(4):386–393. doi: 10.1002/pds.3390
   PubMed Web of Science ®Google Scholar
• Richardson E, Seibert T, Uli NK. Growth perturbations from stimulant medications and inhaled corticosteroids. Transl Pediatr. 2017;6(4):237–247. doi: 10.21037/tp.2017.09.14
   PubMed Web of Science ®Google Scholar
• Schneider G, Banaschewski T, Feldman BL, et al. Weight and height in children and adolescents with attention-deficit/Hyperactivity disorder: a longitudinal database study assessing the impact of guanfacine, stimulants, and no pharmacotherapy. J Child Adolesc Psychopharmacol. 2019;29(4):285–304. doi: 10.1089/cap.2018.0132
   PubMed Web of Science ®Google Scholar
• Swanson JM, Greenhill LL, Wigal T, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304–1313. doi: 10.1097/01.chi.0000235075.25038.5a
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Swanson JM, Hechtman L, et al. Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-deficit/Hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2020;59(8):978–989. doi: 10.1016/j.jaac.2019.06.019
   PubMed Web of Science ®Google Scholar
• Swanson JM, Arnold LE, Molina BSG, et al. Young adult outcomes in the follow‐up of the multimodal treatment study of attention‐deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry. 2017;58(6):663–678. doi: 10.1111/jcpp.12684
   PubMed Web of Science ®Google Scholar
• Carucci S, Balia C, Gagliano A, et al. Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2021;120:509–525. doi: 10.1016/j.neubiorev.2020.09.031
   PubMed Web of Science ®Google Scholar
• Martins-Silva T, JdS V, Genro JP, et al. Obesity and ADHD: exploring the role of body composition, BMI polygenic risk score, and reward system genes. J Psychiatr Res. 2021;136:529–536. doi: 10.1016/j.jpsychires.2020.10.026
   PubMed Web of Science ®Google Scholar
• Cortese S, Tessari L. Attention-deficit/Hyperactivity disorder (ADHD) and obesity: update 2016. Curr Psychiatry Rep. 2017;19(1):4–4. doi: 10.1007/s11920-017-0754-1
   PubMed Web of Science ®Google Scholar
• Feuer AJ, Thai A, Demmer RT, et al. Association of stimulant medication use with bone mass in children and adolescents with attention-deficit/Hyperactivity disorder. JAMA Pediatr. 2016;170(12):e162804–e162804. doi: 10.1001/jamapediatrics.2016.2804
   PubMed Web of Science ®Google Scholar
• Chang Z, Quinn PD, O’Reilly L, et al. Medication for attention-deficit/Hyperactivity disorder and risk for suicide attempts. Biological Psychiatry (1969). 2020;88(6):452–458. doi: 10.1016/j.biopsych.2019.12.003
   PubMed Web of Science ®Google Scholar
• Huang K-L, Wei H-T, Hsu J-W, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. Br J Psychiatry. 2018;212(4):234–238. doi: 10.1192/bjp.2018.8
   PubMed Web of Science ®Google Scholar
• Liu WJ, Mao HJ, Hu LL, et al. Attention‐deficit/hyperactivity disorder medication and risk of suicide attempt: a meta‐analysis of observational studies. Pharmacoepidemiol Drug Saf. 2020;29(11):1364–1372. doi: 10.1002/pds.5110
   PubMed Web of Science ®Google Scholar
• Man KKC, Coghill D, Chan EW, et al. Association of risk of suicide attempts with methylphenidate treatment. JAMA psychiatry (Chicago, Ill). JAMA Psychiatry. 2017;74(10):1048–1055. doi: 10.1001/jamapsychiatry.2017.2183
   PubMed Web of Science ®Google Scholar
• Park J, Lee DY, Kim C, et al. Long-term methylphenidate use for children and adolescents with attention deficit hyperactivity disorder and risk for depression, conduct disorder, and psychotic disorder: a nationwide longitudinal cohort study in South Korea. Child Adolesc Psychiatr Ment Health. 2022;16(1):1–80. doi: 10.1186/s13034-022-00515-5
   PubMed Web of Science ®Google Scholar
• Chang Z, D’Onofrio BM, Quinn PD, et al. Medication for attention deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biological Psychiatry (1969). 2016;80(12):916–922. doi: 10.1016/j.biopsych.2016.02.018
   PubMed Web of Science ®Google Scholar
• Davies M, Coughtrie A, Layton D, et al. Use of atomoxetine and suicidal ideation in children and adolescents: results of an observational cohort study within general practice in England. Eur Psychiatry. 2016;39:11–16. doi: 10.1016/j.eurpsy.2016.06.005
   PubMed Web of Science ®Google Scholar
• Capuano A, Scavone C, Rafaniello C, et al. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation. Expert Opin Drug Saf. 2014;13(S1):69–78. doi: 10.1517/14740338.2014.941804
   Google Scholar
• Breyer JL, Lee S, Winters KC, et al. A longitudinal study of childhood ADHD and substance dependence disorders in early adulthood. Psychol Addict Behav. 2014;28(1):238–246. doi: 10.1037/a0035664
   PubMed Web of Science ®Google Scholar
• Charach A, Yeung E, Climans T, et al. Childhood attention-deficit/Hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50(1):9–21. doi: 10.1016/j.jaac.2010.09.019
   PubMed Web of Science ®Google Scholar
• Groenman AP, Janssen TWP, Oosterlaan J. Childhood psychiatric disorders as risk factor for subsequent substance abuse: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(7):556–569. doi: 10.1016/j.jaac.2017.05.004
   PubMed Web of Science ®Google Scholar
• Wilens TE, Martelon M, Joshi G, et al. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011;50(6):543–553. doi: 10.1016/j.jaac.2011.01.021
   PubMed Web of Science ®Google Scholar
• Volkow ND. Long-term safety of stimulant use for ADHD. Findings From Nonhuman Primates Neuropsychopharmacology.( New York, NY) 2012;37(12):2551–2552. doi: 10.1038/npp.2012.127
   PubMed Web of Science ®Google Scholar
• Sundquist J, Ohlsson H, Sundquist K, et al. Attention-deficit/hyperactivity disorder and risk for drug use disorder: a population-based follow-up and co-relative study. Psychol Med. 2015;45(5):977–983. doi: 10.1017/S0033291714001986
   PubMed Web of Science ®Google Scholar
• Steinhausen H-C, Bisgaard C. Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. Eur Neuropsychopharmacol. 2013;24(2):232–241. doi: 10.1016/j.euroneuro.2013.11.003
   PubMed Web of Science ®Google Scholar
• Molina BSG, Hinshaw SP, Arnold EL, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/Hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52(3):250–263. doi: 10.1016/j.jaac.2012.12.014
   PubMed Web of Science ®Google Scholar
• Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA psychiatry (Chicago, Ill). JAMA Psychiatry. 2013;70(7):1–9. doi: 10.1001/jamapsychiatry.2013.1273
   PubMed Web of Science ®Google Scholar
• Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878–885. doi: 10.1111/jcpp.12164
   PubMed Web of Science ®Google Scholar
• McCabe SE, Dickinson K, West BT, et al. Age of onset, duration, and type of medication therapy for attention-deficit/Hyperactivity disorder (ADHD) and substance use during adolescence: a multi-cohort national study. J Am Acad Child Adolesc Psychiatry. 2016;55(6):479–486. doi: 10.1016/j.jaac.2016.03.011
   PubMed Web of Science ®Google Scholar
• Quinn PD, Chang Z, Hur K, et al. ADHD medication and substance-related problems. Am J Psychiatry. 2017;174(9):877–885. doi: 10.1176/appi.ajp.2017.16060686
   PubMed Web of Science ®Google Scholar
• Johnston LD, O'Malley PM, Miech RA, et al. Monitoring the Future national survey results on drug use: 1975-2014: overview, key findings on adolescent drug use. Ann Arbor (MI): Institute for Social Research, The University of Michigan; 2015.
   Google Scholar
• Dalsgaard S, Mortensen PB, Frydenberg M, et al. Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood. Eur Psychiatry. 2014;29(4):259–263. doi: 10.1016/j.eurpsy.2013.06.004
   PubMed Web of Science ®Google Scholar
• Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(7):1149–1152. doi: 10.1176/ajp.2006.163.7.1149
   PubMed Web of Science ®Google Scholar
• Hollis C, Chen Q, Chang Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry. 2019;6(8):651–658. doi: 10.1016/S2215-0366(19)30189-0
   PubMed Web of Science ®Google Scholar
• Man KKC, Coghill D, Chan EW, et al. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry. 2016;6(11):e956–e956. doi: 10.1038/tp.2016.216
   PubMedGoogle Scholar
• Shyu Y-C, Yuan S-S, Lee S-Y, et al. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population-based study in Taiwan. Schizophr Res. 2015;168(1):161–167. doi: 10.1016/j.schres.2015.08.033
   PubMed Web of Science ®Google Scholar
• MacKenzie LE, Abidi S, Fisher HL, et al. Stimulant medication and psychotic symptoms in offspring of parents with mental illness. Pediatrics (Evanston). 2016;137(1):1. doi: 10.1542/peds.2015-2486
   Web of Science ®Google Scholar
• Moran LV, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380(12):1128–1138. doi: 10.1056/NEJMoa1813751
   PubMed Web of Science ®Google Scholar
• Millichap JG. Risk of tics with psychostimulants for ADHD. Pediatr Neurol Briefs. 2015;29(12):95–95. doi: 10.15844/pedneurbriefs-29-12-6
   PubMedGoogle Scholar
• Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54(9):728–736. doi: 10.1016/j.jaac.2015.06.011
   PubMed Web of Science ®Google Scholar
• Ogundele MO, Ayyash HF, Skeete I. G421 Evidence-based management of tics in children with adhd. Arch of Dise in Child. 2017;102(Suppl 1):A165.
   PubMedGoogle Scholar
• Osland S, Steeves T, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018;2018(6). doi: 10.1002/14651858.CD007990.pub3
   Google Scholar
• Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: treatment of attention-deficit/Hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48(9):884–893. doi: 10.1097/CHI.0b013e3181b26e9f
   PubMed Web of Science ®Google Scholar
• Hodgkins P, Shaw M, Coghill D, et al. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012 Sep;21(9):477–492. doi: 10.1007/s00787-012-0286-5
   PubMed Web of Science ®Google Scholar
• Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/Hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022 Sep 1;42(5):429–439. doi: 10.1097/JCP.0000000000001575
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Hyman D, Parks GS, et al. Solriamfetol titration & Administration (START) in patients with narcolepsy. Clin Ther. 2022 Oct;44(10):1356–1369. doi: 10.1016/j.clinthera.2022.08.012
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration NDA 211230/Original 1 NDA Accessed 5 Feb 2023 Approval available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211230Orig1s000,%20Orig2s000ltr.pdf
   Google Scholar
• Surman C A controlled study of solriamfetol for ADHD in adults.Accessed 14 May 2023 Available at https://clinicaltrials.gov/ct2/results?term=solriamfetol&cond=Adhd
   Google Scholar
• Surman C, Vaudreuil C, Boland H, et al. L-Threonic acid magnesium salt supplementation in ADHD: an open-label Pilot study. J Diet Suppl. 2021;18(2):119–131. doi: 10.1080/19390211.2020.1731044
   PubMed Web of Science ®Google Scholar
• Jan 4, 2023 Cingulate initiates phase 3 study of lead asset CTx-1301, designed as a true entire active-day treatment for ADHD accessed 05 Feb 2023. available from: https://www.cingulate.com/news-releases/news-release-details/cingulate-initiates-phase-3-study-lead-asset-ctx-1301-designed
   Google Scholar
• Childress AC, Beltran N, Supnet C, et al. Reviewing the role of emerging therapies in the ADHD armamentarium. Expert Opin Emerg Drugs. 2021;26(1):1–16. doi: 10.1080/14728214.2020.1846718
   PubMed Web of Science ®Google Scholar